中新财经1月29日电(记者 张尼)记者从国家医保局获悉，针对阿斯利康制药有限公司工作人员涉嫌篡改肿瘤患者基因检测结果骗取医保基金的情况，国家医保局基金监管司负责人表示，前期根据群众举报线索，国家医保局督促深圳市成立了医保、公安、卫生健康、市场监管等部门组成的联合专案组，对案件情况进行深入调查，犯罪嫌疑人已全部被批捕。
近期，国家医保局联合公安部对阿斯利康中国有关负责人进行了约谈，通报了案件阶段性调查进展，要求阿斯利康中国严格遵守法律法规，全力配合有关部门做好后续调查，并立即开展内部排查整改、堵塞营销监管漏洞，加强员工守法教育、切实增强诚信意识，适时曝光约谈及整改情况。
阿斯利康中国按照约谈要求，及时对接深圳市医保局和公安局做好案件后续侦办工作，督促员工有类似行为的主动投案自首，并在企业官网公布案件和自查整改情况。
下一步，国家医保局将联合公安部、国家卫生健康委在全国范围内对篡改基因检测结果骗取医保基金行为开展专项整治，重拳出击，全面排查，依法依规严厉打击此类欺诈骗保行为，坚决守护好人民群众的“看病钱”“救命钱”。
国家医保局也督促相关企业和人员有类似行为的，立即到所在地医保部门和公安部门投案自首，争取宽大处理。
记者注意到，日前，阿斯利康在官网发布公告称，阿斯利康自进入中国以来，始终恪守国家相关法律法规，要求全体员工严格遵守国家法律法规和公司规章制度，对任何违法违纪行为坚持零容忍的态度。
2021年8月，阿斯利康在内部合规检查中发现，深圳市有少数员工存在篡改或参与篡改患者检测报告的行为，涉嫌骗取医保基金。依据合规政策，公司对这些违反公司规章制度的员工进行了严肃的处理，第一时间主动向地方医保部门汇报，表明公司的态度，并积极协助政府调查。
On December 27, 2021, the National Medical Insurance Administration and the Ministry of Public Security jointly interviewed AstraZeneca China.
At the meeting, relevant departments introduced the investigation of the suspected insurance fraud case in Shenzhen, and put forward relevant suggestions for improvement.
The company attaches great importance to this, sincerely accepts the guidance and suggestions of the National Medical Insurance Bureau and the public security department, and will fully implement relevant requirements, further strengthen management and supervision, and continuously improve employees' awareness of laws and regulations to ensure that legal compliance is implemented to each employee. in daily work.
The company will continue to carry out targeted internal self-examination and self-correction actions to prevent any suspected violations of laws and disciplines such as insurance fraud.
At the same time, AstraZeneca China will continue to strengthen the compliance culture, compliance training system and self-inspection and self-inspection system, and strengthen supervision of business activities to ensure the sustainable and healthy development of the company's business under the premise of legal compliance.
AstraZeneca China will, as always, continue to deepen its efforts in the Chinese market, adhering to the company values of "patient first" and "win-win", to provide more innovative drugs for Chinese patients.
(Finish)